Skip to main content
Erschienen in: Supportive Care in Cancer 7/2013

01.07.2013 | Original Article

Outcomes in critically ill chronic lymphocytic leukemia patients

verfasst von: Aliénor Xhaard, Loic Epelboin, David Schnell, François Vincent, Vincent Levy, Marion Malphettes, Élie Azoulay, Michaël Darmon

Erschienen in: Supportive Care in Cancer | Ausgabe 7/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

Although recent studies have demonstrated an improvement in the prognosis of critically ill cancer patients, little is known regarding the prognosis of patients with non-aggressive underlying malignancies. The aims of this study were to assess the prognosis of critically ill patients with chronic lymphocytic leukemia (CLL) and to evaluate risk factors for hospital mortality.

Methods

In retrospective mono-center cohort study, consecutive adult patients with CLL requiring ICU admission from 1997 to 2008 were included.

Results

Sixty-two patients of 67 years (62–75) were included. Median time interval between CLL diagnosis and ICU admission was 6.7 years (2.6–10.8). Nine patients (15 %) had stage C disease at the time of ICU admission, and seven patients (11 %) had Richter syndrome. Most ICU admissions were related to bacterial or fungal pulmonary infections (n = 47; 76 %). ICU, in-hospital, and 90-day mortality were 35 % (n = 22), 42 % (n = 26), and 58 % (n = 36), respectively. Only three factors were independently associated with in-hospital mortality: oxygen saturation lower than 95 % when breathing room air (odds ratio (OR) 5.80; 95 % confidence interval (CI) 1.23–27.33), need for vasopressors (OR 27.94; 95 % CI 5.37–145.4), and past history of infection (OR 6.62; 95 % CI 1.34–32.68). The final model did not change when disease-related variables (Binet classification, Richter syndrome, long-term steroids) or treatment-related variables (fludarabine, rituximab, or alemtuzumab) were included.

Conclusion

Acute pulmonary infections remain the leading cause of ICU admission in patients with CLL. The severity at ICU admission and past history of infection were the only factors associated with hospital mortality. Neither disease characteristics nor previous cancer treatments were associated with outcome.
Literatur
1.
Zurück zum Zitat Carlon GC (1988) Admitting cancer patients to the intensive care unit. Crit Care Clin 4:183–191PubMed Carlon GC (1988) Admitting cancer patients to the intensive care unit. Crit Care Clin 4:183–191PubMed
2.
Zurück zum Zitat Lloyd-Thomas AR, Dhaliwal HS, Lister TA et al (1986) Intensive therapy for life-threatening medical complications of haematological malignancy. Intensive Care Med 12:317–324PubMedCrossRef Lloyd-Thomas AR, Dhaliwal HS, Lister TA et al (1986) Intensive therapy for life-threatening medical complications of haematological malignancy. Intensive Care Med 12:317–324PubMedCrossRef
3.
Zurück zum Zitat Groeger JS, Lemeshow S, Price K et al (1998) Multicenter outcome study of cancer patients admitted to the intensive care unit: a probability of mortality model. J Clin Oncol 16:761–770PubMed Groeger JS, Lemeshow S, Price K et al (1998) Multicenter outcome study of cancer patients admitted to the intensive care unit: a probability of mortality model. J Clin Oncol 16:761–770PubMed
4.
Zurück zum Zitat Afessa B, Tefferi A, Hoagland HC et al (1992) Outcome of recipients of bone marrow transplants who require intensive-care unit support. Mayo Clin Proc 67:117–122PubMedCrossRef Afessa B, Tefferi A, Hoagland HC et al (1992) Outcome of recipients of bone marrow transplants who require intensive-care unit support. Mayo Clin Proc 67:117–122PubMedCrossRef
5.
Zurück zum Zitat Darmon M, Azoulay E (2009) Critical care management of cancer patients: cause for optimism and need for objectivity. Curr Opin Oncol 21:318–326PubMedCrossRef Darmon M, Azoulay E (2009) Critical care management of cancer patients: cause for optimism and need for objectivity. Curr Opin Oncol 21:318–326PubMedCrossRef
6.
Zurück zum Zitat Azoulay E, Soares M, Darmon M et al (2011) Intensive care of the cancer patient: recent achievements and remaining challenges. Ann Intensive Care 1:5PubMedCrossRef Azoulay E, Soares M, Darmon M et al (2011) Intensive care of the cancer patient: recent achievements and remaining challenges. Ann Intensive Care 1:5PubMedCrossRef
7.
Zurück zum Zitat Soares M, Caruso P, Silva E et al (2010) Characteristics and outcomes of patients with cancer requiring admission to intensive care units: a prospective multicenter study. Crit Care Med 38:9–15PubMedCrossRef Soares M, Caruso P, Silva E et al (2010) Characteristics and outcomes of patients with cancer requiring admission to intensive care units: a prospective multicenter study. Crit Care Med 38:9–15PubMedCrossRef
8.
Zurück zum Zitat Benoit DD, Vandewoude KH, Decruyenaere JM et al (2003) Outcome and early prognostic indicators in patients with a hematologic malignancy admitted to the intensive care unit for a life-threatening complication. Crit Care Med 31:104–112PubMedCrossRef Benoit DD, Vandewoude KH, Decruyenaere JM et al (2003) Outcome and early prognostic indicators in patients with a hematologic malignancy admitted to the intensive care unit for a life-threatening complication. Crit Care Med 31:104–112PubMedCrossRef
9.
Zurück zum Zitat Peters SG, Meadows JA 3rd, Gracey DR (1988) Outcome of respiratory failure in hematologic malignancy. Chest 94:99–102PubMedCrossRef Peters SG, Meadows JA 3rd, Gracey DR (1988) Outcome of respiratory failure in hematologic malignancy. Chest 94:99–102PubMedCrossRef
10.
Zurück zum Zitat Brenner H (2002) Long-term survival rates of cancer patients achieved by the end of the 20th century: a period analysis. Lancet 360:1131–1135PubMedCrossRef Brenner H (2002) Long-term survival rates of cancer patients achieved by the end of the 20th century: a period analysis. Lancet 360:1131–1135PubMedCrossRef
11.
Zurück zum Zitat Chiorazzi N, Rai KR, Ferrarini M (2005) Chronic lymphocytic leukemia. N Engl J Med 352:804–815PubMedCrossRef Chiorazzi N, Rai KR, Ferrarini M (2005) Chronic lymphocytic leukemia. N Engl J Med 352:804–815PubMedCrossRef
12.
Zurück zum Zitat Wierda WG (2006) Current and investigational therapies for patients with CLL. Hematology Am Soc Hematol Educ Program 285–94 Wierda WG (2006) Current and investigational therapies for patients with CLL. Hematology Am Soc Hematol Educ Program 285–94
13.
Zurück zum Zitat Morrison VA (2010) Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approaches. Best Pract Res Clin Haematol 23:145–153PubMedCrossRef Morrison VA (2010) Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approaches. Best Pract Res Clin Haematol 23:145–153PubMedCrossRef
14.
Zurück zum Zitat Lepretre S, Aurran T, Mahé B et al (2012) Excess mortality following FCCam treatment in previously untreated patients with CLL: safety and efficacy in a randomized, multicenter, phase III trial. Blood. doi:10.1182/blood-2011-07-365437 Lepretre S, Aurran T, Mahé B et al (2012) Excess mortality following FCCam treatment in previously untreated patients with CLL: safety and efficacy in a randomized, multicenter, phase III trial. Blood. doi:10.​1182/​blood-2011-07-365437
15.
Zurück zum Zitat Skoetz N, Bauer K, Elter T et al (2012) Alemtuzumab for patients with chronic lymphocytic leukaemia. Cochrane Database Syst Rev 2:CD008078PubMed Skoetz N, Bauer K, Elter T et al (2012) Alemtuzumab for patients with chronic lymphocytic leukaemia. Cochrane Database Syst Rev 2:CD008078PubMed
16.
Zurück zum Zitat Azoulay E, Thiéry G, Chevret S et al (2004) The prognosis of acute respiratory failure in critically ill cancer patients. Med (Baltimore) 83:360–370CrossRef Azoulay E, Thiéry G, Chevret S et al (2004) The prognosis of acute respiratory failure in critically ill cancer patients. Med (Baltimore) 83:360–370CrossRef
17.
Zurück zum Zitat Peigne V, Rusinová K, Karlin L et al (2009) Continued survival gains in recent years among critically ill myeloma patients. Intensive Care Med 35:512–518PubMedCrossRef Peigne V, Rusinová K, Karlin L et al (2009) Continued survival gains in recent years among critically ill myeloma patients. Intensive Care Med 35:512–518PubMedCrossRef
18.
Zurück zum Zitat Binet JL, Auquier A, Dighiero G et al (1981) A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48:198–206PubMedCrossRef Binet JL, Auquier A, Dighiero G et al (1981) A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48:198–206PubMedCrossRef
19.
Zurück zum Zitat Le Gall JR, Klar J, Lemeshow S et al (1996) The logistic organ dysfunction system. A new way to assess organ dysfunction in the intensive care unit. ICU Scoring Group. JAMA 276:802–810PubMedCrossRef Le Gall JR, Klar J, Lemeshow S et al (1996) The logistic organ dysfunction system. A new way to assess organ dysfunction in the intensive care unit. ICU Scoring Group. JAMA 276:802–810PubMedCrossRef
20.
Zurück zum Zitat Muckart DJ, Bhagwanjee S (1997) American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference definitions of the systemic inflammatory response syndrome and allied disorders in relation to critically injured patients. Crit Care Med 25:1789–1795PubMedCrossRef Muckart DJ, Bhagwanjee S (1997) American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference definitions of the systemic inflammatory response syndrome and allied disorders in relation to critically injured patients. Crit Care Med 25:1789–1795PubMedCrossRef
21.
Zurück zum Zitat Anonymous (1995) Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society. Am J Respir Crit Care Med 152:S77–121 Anonymous (1995) Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society. Am J Respir Crit Care Med 152:S77–121
22.
Zurück zum Zitat Legrand M, Max A, Peigne V et al (2012) Survival in neutropenic patients with severe sepsis or septic shock. Crit Care Med 40:43–49PubMedCrossRef Legrand M, Max A, Peigne V et al (2012) Survival in neutropenic patients with severe sepsis or septic shock. Crit Care Med 40:43–49PubMedCrossRef
23.
Zurück zum Zitat Depuydt P, Benoit D, Vogelaers D et al (2006) Outcome in bacteremia associated with nosocomial pneumonia and the impact of pathogen prediction by tracheal surveillance cultures. Intensive Care Med 32:1773–1781PubMedCrossRef Depuydt P, Benoit D, Vogelaers D et al (2006) Outcome in bacteremia associated with nosocomial pneumonia and the impact of pathogen prediction by tracheal surveillance cultures. Intensive Care Med 32:1773–1781PubMedCrossRef
24.
Zurück zum Zitat Morrison VA (2007) Management of infectious complications in patients with chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 332–8 Morrison VA (2007) Management of infectious complications in patients with chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 332–8
25.
Zurück zum Zitat Francis S, Karanth M, Pratt G et al (2006) The effect of immunoglobulin VH gene mutation status and other prognostic factors on the incidence of major infections in patients with chronic lymphocytic leukemia. Cancer 107:1023–1033PubMedCrossRef Francis S, Karanth M, Pratt G et al (2006) The effect of immunoglobulin VH gene mutation status and other prognostic factors on the incidence of major infections in patients with chronic lymphocytic leukemia. Cancer 107:1023–1033PubMedCrossRef
26.
Zurück zum Zitat Ravandi F, O’Brien S (2006) Immune defects in patients with chronic lymphocytic leukemia. Cancer Immunol Immunother 55:197–209PubMedCrossRef Ravandi F, O’Brien S (2006) Immune defects in patients with chronic lymphocytic leukemia. Cancer Immunol Immunother 55:197–209PubMedCrossRef
27.
Zurück zum Zitat Wadhwa PD, Morrison VA (2006) Infectious complications of chronic lymphocytic leukemia. Semin Oncol 33:240–249PubMedCrossRef Wadhwa PD, Morrison VA (2006) Infectious complications of chronic lymphocytic leukemia. Semin Oncol 33:240–249PubMedCrossRef
28.
Zurück zum Zitat Molica S, Levato D, Levato L (1993) Infections in chronic lymphocytic leukemia. Analysis of incidence as a function of length of follow-up. Haematologica 78:374–377PubMed Molica S, Levato D, Levato L (1993) Infections in chronic lymphocytic leukemia. Analysis of incidence as a function of length of follow-up. Haematologica 78:374–377PubMed
29.
Zurück zum Zitat Eichhorst BF, Busch R, Schweighofer C et al (2007) Due to low infection rates no routine anti-infective prophylaxis is required in younger patients with chronic lymphocytic leukaemia during fludarabine-based first line therapy. Br J Haematol 136:63–72PubMedCrossRef Eichhorst BF, Busch R, Schweighofer C et al (2007) Due to low infection rates no routine anti-infective prophylaxis is required in younger patients with chronic lymphocytic leukaemia during fludarabine-based first line therapy. Br J Haematol 136:63–72PubMedCrossRef
30.
Zurück zum Zitat Hensel M, Kornacker M, Yammeni S et al (2003) Disease activity and pretreatment, rather than hypogammaglobulinaemia, are major risk factors for infectious complications in patients with chronic lymphocytic leukaemia. Br J Haematol 122:600–606PubMedCrossRef Hensel M, Kornacker M, Yammeni S et al (2003) Disease activity and pretreatment, rather than hypogammaglobulinaemia, are major risk factors for infectious complications in patients with chronic lymphocytic leukaemia. Br J Haematol 122:600–606PubMedCrossRef
31.
Zurück zum Zitat Lin TS, Donohue KA, Byrd JC et al (2010) Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101. J Clin Oncol 28:4500–4506PubMedCrossRef Lin TS, Donohue KA, Byrd JC et al (2010) Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101. J Clin Oncol 28:4500–4506PubMedCrossRef
32.
Zurück zum Zitat Schweighofer CD, Ritgen M, Eichhorst BF et al (2009) Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). Br J Haematol 144:95–98PubMedCrossRef Schweighofer CD, Ritgen M, Eichhorst BF et al (2009) Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). Br J Haematol 144:95–98PubMedCrossRef
33.
Zurück zum Zitat Badoux XC, Keating MJ, Wang X et al (2011) Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia. Blood 118:2085–2093PubMedCrossRef Badoux XC, Keating MJ, Wang X et al (2011) Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia. Blood 118:2085–2093PubMedCrossRef
34.
Zurück zum Zitat Schellongowski P, Staudinger T, Kundi M et al (2011) Prognostic factors for intensive care unit admission, intensive care outcome, and post-intensive care survival in patients with de novo acute myeloid leukemia: a single center experience. Haematologica 96:231–237PubMedCrossRef Schellongowski P, Staudinger T, Kundi M et al (2011) Prognostic factors for intensive care unit admission, intensive care outcome, and post-intensive care survival in patients with de novo acute myeloid leukemia: a single center experience. Haematologica 96:231–237PubMedCrossRef
35.
Zurück zum Zitat Thakkar SG, Fu AZ, Sweetenham JW, Mciver ZA et al (2008) Survival and predictors of outcome in patients with acute leukemia admitted to the intensive care unit. Cancer 112:2233–2240PubMedCrossRef Thakkar SG, Fu AZ, Sweetenham JW, Mciver ZA et al (2008) Survival and predictors of outcome in patients with acute leukemia admitted to the intensive care unit. Cancer 112:2233–2240PubMedCrossRef
36.
Zurück zum Zitat Darmon M, Azoulay E, Alberti C et al (2002) Impact of neutropenia duration on short-term mortality in neutropenic critically ill cancer patients. Intensive Care Med 28:1775–1780PubMedCrossRef Darmon M, Azoulay E, Alberti C et al (2002) Impact of neutropenia duration on short-term mortality in neutropenic critically ill cancer patients. Intensive Care Med 28:1775–1780PubMedCrossRef
Metadaten
Titel
Outcomes in critically ill chronic lymphocytic leukemia patients
verfasst von
Aliénor Xhaard
Loic Epelboin
David Schnell
François Vincent
Vincent Levy
Marion Malphettes
Élie Azoulay
Michaël Darmon
Publikationsdatum
01.07.2013
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 7/2013
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-013-1744-4

Weitere Artikel der Ausgabe 7/2013

Supportive Care in Cancer 7/2013 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.